Drug-related adverse events may predict efficacy in sorafenib therapy for hepatocellular carcinoma.
Yan
Y
Zhao
Man
M
Yang
Xingshun
X
Qi
Guohong
G
Han
Daiming
D
Fan
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001557:Benzenesulfonates / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D011725:Pyridines / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D011725:Pyridines